Clinical Trial

Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia

Study acronym: PE-POSS
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 20, 2026 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-08.
Trial Details
NCT Number NCT07349277
Lead Sponsor Ammar Jassim Abed
Conditions Preeclampsia, Gestational Hypertension, Hypertensive Disorders of Pregnancy
Enrollment 120 participants
Start Date 2025-10-10
Primary Completion 2026-01-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-20